Researchers in UT Pharmacy's Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs have earned a bevy of national and international awards for their work in pharmaceutical drug delivery and 3D printing personalized medicines.
Tara Law from Time writes about how few pharmacies carry buprenorphine, a life-saving drug to help treat opioid use disorder (OUD). Lucas Hill, Pharm.D., BCACP, director of the college's Pharmacy Addictions Research & Medicine (PhARM) program, offers his insight on the issue, and how the DEA's crackdown of the drug puts OUD patients at risk.
Dr. Mo Maniruzzaman's Pharmaceutical Engineering and 3D Printing Labs have received a federal grant from the United States Agency for International Development (USAID) to develop personalized 3D printed non-hormonal intrauterine devices (IUDs). The project’s goal is to increase global access to long-term and effective contraception while minimizing some of its most debilitating side effects.
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.
The college's Pharmaceutical Engineering and 3D Printing (PharmE3D) labs, led by Assistant Professor in Molecular Pharmaceutics and Drug Delivery Mohammed (Mo) Maniruzzaman, Ph.D., has recently earned several national and international awards and scholarships for outstanding research contributions to the field of pharmaceutical science and technology.
Division Head and Professor of Molecular Pharmaceutics and Drug Delivery Dr. Bill Williams was on KXAN News to talk about promising new data from TFF Pharmaceuticals and Augmenta Bioworks. The companies plan to develop Dr. Williams' thin film freezing technology to better deliver antibody treatment directly to the lungs of COVID patients.
Nathan Pope, Pharm.D., BCACP, FACA has been named The University of Texas at Austin College of Pharmacy’s new assistant dean of experiential education and will succeed Jennifer Ridings-Myhra, M.Ed., R.Ph., who plans to work with Dr. Pope through July and August to assist in the transition. The start date for this new role is effective July 1, 2021.